{
  "id": 14404217,
  "title": "Nxera Pharma Signs Exclusive QUVIVIQ Licensing Deal With Synmosa For Eight Markets",
  "url": "https://urgent.news/2026/10/14/nxera-pharma-signs-exclusive-quviviq-licensing-deal-with-synmosa-for",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T08:13:35.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/nxera-pharma-signs-exclusive-quviviq-licensing-deal-synmosa-eight-markets"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Nxera Pharma Co., Ltd. (4565.T), a technology-powered biopharmaceutical company, on Wednesday announced an exclusive licensing, supply and commercialization agreement with Synmosa Biopharma Corp. (4114.TWO).",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}